Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more

Bibliographic Details
Title: Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more
Authors: Marie Cathrin Mayer, Edgar Meinl
Source: Therapeutic Advances in Neurological Disorders, Vol 5 (2012)
Publisher Information: SAGE Publishing, 2012.
Publication Year: 2012
Collection: LCC:Neurology. Diseases of the nervous system
Subject Terms: Neurology. Diseases of the nervous system, RC346-429
More Details: B cells and antibodies constitute an important element in different inflammatory diseases of the central nervous system (CNS). Autoantibodies can serve as a biomarker to identify disease subgroups and may in addition contribute to the pathogenic process. One candidate autoantigen for multiple sclerosis (MS) is myelin oligodendrocyte glycoprotein (MOG). MOG is localized at the outermost surface of myelin in the CNS and has been the focus of extensive research for more than 30 years. Its role as an important autoantigen for T cells and as a target of demyelinating autoantibodies has been established in several variants of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The literature regarding antibodies to MOG in MS patients is confusing and contradictory. Recent studies, however, have described high levels of antibodies to conformationally correct MOG in pediatric acquired demyelination, both acute disseminated encephalomyelitis (ADEM) and MS. In adult MS, such antibodies are rarely found and then only at low levels. In this review, we summarize key findings from animal models and patient studies, discuss challenges in detecting anti-MOG antibodies in patients and present recent approaches to identifying new autoantigens in MS.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1756-2856
1756-2864
17562856
Relation: https://doaj.org/toc/1756-2856; https://doaj.org/toc/1756-2864
DOI: 10.1177/1756285611433772
Access URL: https://doaj.org/article/61a0a34ae01340009735c4ece87cc39e
Accession Number: edsdoj.61a0a34ae01340009735c4ece87cc39e
Database: Directory of Open Access Journals
More Details
ISSN:17562856
17562864
DOI:10.1177/1756285611433772
Published in:Therapeutic Advances in Neurological Disorders
Language:English